// App-Quantinova.ai

Su1936 : ETROLIZUMAB TREATMENT LEADS TO EARLY IMPROVEMENT IN SYMPTOMS AND INFLAMMATORY BIOMARKERS IN ANTI-TNF-REFRACTORY PATIENTS IN THE OPEN-LABEL INDUCTION COHORT OF THE PHASE 3 HICKORY STUDY

Researchers

Presenter

  • Brian G. Feagan

Principal Investigators

  • John Mansfield

  • David T. Rubin

  • Udayasankar Arulmani

  • Romeo Maciuca

  • Helen Tyrrell

  • James Thommes

  • Swati Tole

Medical Centers

  • University of Western Ontario, London, ON, Canada

  • Rush University Medical Center, Chicago, Illinois, United States

  • Newcastle University, Newcastle upon Tyne, United Kingdom

  • Universite de Lorraine, Vandoeuvre les Nancy, France

Locations

  • United States

  • Canada

  • France

  • United Kingdom

Companies

  • F. Hoffmann-La Roche

  • Genentech, Inc.

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • C reactive protein

Drug/Treatment

  • Etrolizumab

Outcome

  • Unknown

Study Design

  • open label

  • randomized

  • double blind/blinded

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved